Targeting the Epithelial Alarmin Axis with Biomedical Nanoparticles: A New Frontier in Allergic Asthma Therapy
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Allergic asthma is a chronic inflammatory airway disease driven by type 2 immune responses, whose pathogenesis correlates with the release of epithelial alarm proteins-thymic stromal lymphopoietin (TSLP), interleukin-25 (IL-25), and interleukin-33 (IL-33)-by airway epithelial cells following barrier injury. This paper systematically reviews the cutting-edge applications of nanoparticles (NPs) in targeting the epithelial alarmin signaling axis and its downstream immune cells, including dendritic cells, macrophages, Th2 cells, and regulatory T cells. By systematically reviewing research progress on nanoparticles in allergic asthma treatment, this review provides crucial theoretical support and technical frameworks for developing precise, efficient, and less-side-effect asthma therapies. It offers forward-looking guidance for advancing asthma treatment from laboratory to clinical translation.
Fields of Study & Subjects
Asthma and respiratory diseases
IL-33
ST2
and ILC Pathways
Allergic Rhinitis and Sensitization
Publication details
- Journal / source
- International Journal of Nanomedicine
- Volume
- Volume 21
- Pages
- 1–16
- Publication date
- 1 March 2026
- Language
- EN